The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

Table 9

Registry data of outcomes of reduced intensity conditioned (RIC) allogeneic transplants in relapsed and refractory Hodgkin’s lymphoma. Numbers in bold are statistically significant with 𝑃 values where significant. *Antithymocyte globulin given to unrelated donor recipients. Abbreviations: Sib/UD: sibling/unrelated donor; PFS: progression-free survival; OS: overall survival; TRM: treatment-related mortality; M: melphalan; F: fludarabine; A: alemtuzumab; MDACC: MD Anderson Cancer Center; EBMT: European Group for Blood and Marrow Transplantation.

Study; (group, author)	No. of pts	Sib/UD	Median age; (range)	PFS; (%, years)	OS (%)	TRM (%)
RIC	52	−/−	30	42 (2 y)	56	17
(EBMT Robinson 2002)			15–53
MF-A	49	31/18	32	39 (4 y)	56	16 (2 y)
(UK Peggs 2005)			18–51
MF*	40	38/2	31	32 (2 y)	48	25 (1 y)
(Spain Alvarez 2006)			16–53
MF*	58	25/33	32	32 (2 y)	64	15
(MDACC Anderlini 2008)			19–59
Myeloablative	79	70/9	27 (11–60)	20 (5 y)	22	48 (3 y)
RIC	89	77/12	26 (5–61)	18	28	24
(EBMT Sureda 2008)					(.04)	𝑃=.003